In-office endometrial ablation and clinical correlation of reduced menstrual blood loss and effects on dysmenorrhea and premenstrual symptomatology.
OBJECTIVE
To evaluate in-office Thermachoice III endometrial ablation on subsequent dysmenorrhea and premenstrual mood symptoms in relation to decreased menstrual blood loss.


METHODS
The study conducted was in a prospective cohort single group. Ablations were performed on 148 patients under parametrial block using dilute mepivacaine and oral anxiolysis for a diagnosis of menorrhagia. The primary endpoint was eumenorrhea or less, with secondary endpoints of dysmenorrhea reduction and premenstrual symptom alleviation. Patients were evaluated at 3 and 6 months postprocedure. Of 148 patients, 134 (90.5%) complied with follow-up.


RESULTS
At 3 months, 52% were amenorrheic; 48% reporting hypomenorrhea. Results persisted at 6 months, with 50% and 48%, respectfully. Of 134 patients, 3 were considered nonresponders at 6 months. Mean hemoglobin values increased for all groups at each time endpoint. Of 115 patients, 79 reported baseline dysmenorrhea, with improvement in visual analog scale findings at both 3 and 6 months (p<0.005). Premenstrual mood symptoms of agitation, irritability and depression also improved at both 3 and 6 months.


CONCLUSIONS
In-office Thermachoice III endometrial ablation results in decreased dysmenorrhea and improved mood in relation to decreased menstrual blood loss.
Women's Specialty Center, 1135 North Bishop Avenue, Dallas, TX 75208, USA. chapamd@aol.com
Hector O
HO
Chapa
Gonzalo
G
Venegas
Alfred G
AG
Antonetti
Charles P
CP
Van Duyne
Jeffrey
J
Sandate
Ken
K
Bakker
D000328:Adult; D000556:Ambulatory Surgical Procedures; D000772:Anesthesia, Local; D000779:Anesthetics, Local / Q000008:administration & dosage; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D015331:Cohort Studies; D004412:Dysmenorrhea / Q000601:surgery*; D055356:Endometrial Ablation Techniques; D005260:Female; D006801:Humans; D008595:Menorrhagia / Q000601:surgery*; D008619:Mepivacaine / Q000008:administration & dosage; D008875:Middle Aged; D011293:Premenstrual Syndrome / Q000601:surgery*; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
D000779:Anesthetics, Local; D014151:Anti-Anxiety Agents; D008619:Mepivacaine